News | Radiation Oncology | July 06, 2015

New Genetic Testing for Prostate Cancer Offered at New York City Center

MRI-ultrasound fusion biopsies among advanced toolsets for improved pre- and post-biopsy detection of prostate cancer

Dr. Samadi Prostate Cancer Center, New York, biopsy, detection, ultrasound, MRI

July 6, 2015 - The Dr. Samadi Prostate Cancer Center in New York City is now offering a full suite of new genetic testing methods for diagnosing prostate cancer. The new methods are intended for men with an elevated prostate specific antigen (PSA) level or who have had a biopsy.

The center is offering a range of genetic tests for assessing the risk and optimizing the diagnosis of prostate cancer, both pre-biopsy and post-biopsy.

The difference is the role genetic testing plays throughout the entire process, from diagnosis to recurrence. If a man's PSA is elevated, the 4K Score, PcA3, and prostate biopsy can further indicate activity around the prostate as well as support whether to get a biopsy or not. If a biopsy returns positive, the next step is directing the right prostate cancer treatment for each patient. Other genetic testing methods such as Prolaris and OncotypeDx, combined with testing for hereditary PCa and genes like BRCA, will give more information regarding the risk factors, growth rate, aggressiveness and risk of morbidity of the cancer.

The Dr. Samadi Prostate Cancer Center will offer the following genetic tests:

Post-PSA Diagnostic Testing

4K Score: This test measures four prostate-specific kallikreins in the blood: Total PSA, FREE PSA, Intact PSA and Human Kallikrein 2 (hK2). Results are combined with patient age, digital rectal exam (nodule, no nodule) and prior negative biopsy results (yes, no). The tests then provides a percentage probability on a scale of 1-95 for the patient having high-grade prostate cancer. The 4K Score is designed specifically to reduce the number of unnecessary negative biopsies that detect low-grade cancer. This means not all men who have an elevated PSA will require a biopsy.

PCA3 Score: This is a simple urine sample collected following a digital rectal exam for the determination of the PCA3 score. Specific for prostate cancer, and, unlike the PSA, this test is not affected by prostate enlargement or other non-cancerous prostate conditions. In combination with PSA and DRE results, the PCA3 score provides useful information to help decide if a biopsy is needed, or can be delayed. It is much more specific in giving additional information about the aggressiveness of the cancer if the patient has a positive biopsy.

Post-Biopsy Genetic Testing

MRI Guided Biopsy: Dr. Samadi's Prostate Cancer Center uses the Uronav Fusion Biopsy System for magnetic resonance imaging (MRI)-guided biopsy. An MRI-ultrasound fusion biopsy involves taking an MRI and then fusing the data with real-time ultrasound images for guidance on biopsy procedures. The UroNav System combines electromagnetic tracking and navigation with an onboard computer and a real-time imaging interface in one mobile workstation. The MR/ultrasound fusion aligns and registers prior diagnostic MR images with real-time ultrasound images.

Oncotype DX: The Oncotype DX Genomic Prostate Score is a biopsy-based genetic test that can be combined with other measures to predict the aggressiveness of prostate cancer. The test applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions for each individual patient. The test is a multi-gene RT-PCR expression analysis developed to work in combination with prostate needle biopsies. It measures the expression of 12 cancer-related genes representing four biological pathways and 5 reference genes, which are then combined to calculate the Genomic Prostate Score (GPX). This biopsy-based score has been clinically validated as a predictor of aggressive prostate cancer.

Prolaris & Genomic Prostate Score: The purpose of this score is to distinguish between aggressive cancers that need treatment and those that are slow growing and may need active surveillance. The Prolaris Score is a measure of how fast a prostate cancer tumor is growing after a biopsy has indicated its presence in the prostate gland. Biopsy tissue samples are used to determine a patient's personal Prolaris Score. It measures how fast cancer cells in the tumor are dividing. Measuring a 46-gene expression signature, Prolaris also includes cell cycle progression genes selected based upon correlation with prostate tumor cell proliferation.

ConfirmMDx: A genetic test rooted in the field of epigenetics, this test identifies key changes in gene activity for a negative biopsy or results showing high-grade PIN or ASAP. ConfirmMDx was developed to help reduce unnecessary repeat biopsies through its support of the negative predictive value (NPV). Clinical trials showed this test to be the most significant independent predictor for prostate cancer detection on repeat biopsy.

"Now that we've moved from ultrasound to MRI, in combination with these genetic tests, we may actually be to able crack the code and diagnose aggressive prostate cancer earlier. And of course, this leads to the right treatment path for each patient," said Samadi.

For more information: www.prostatecancer911.com

Related Content

New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the...
MRI "Glove" Provides New Look at Hand Anatomy

An experiment showed that a glove-shaped detector could yield images of bones, cartilage, and muscles interacting as a hand 'plays piano.' Traditionally, MRI had required patients to remain strictly motionless.Image courtesy of Nature Biomedical Engineering; Bei Zhang, Martijn Cloos, Daniel Sodickson

News | Magnetic Resonance Imaging (MRI) | May 17, 2018
A new kind of magnetic resonance imaging (MRI) component in the shape of a glove delivers the first clear images of...
FDA Clears Medic Vision's iQMR MRI Image Enhancement Technology

Image courtesy of Medic Vision Imaging Solutions

Technology | Magnetic Resonance Imaging (MRI) | May 15, 2018
May 15, 2018 — Medic Vision Imaging Solutions Ltd. announced that the U.S.
Impaired Brain Pathways May Cause Attention Problems After Stroke
News | Neuro Imaging | May 10, 2018
Damage to some of the pathways that carry information throughout the brain may be responsible for attention deficit in...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
USPSTF Updates Recommendations for Prostate Cancer Screening
News | Prostate Cancer | May 09, 2018
The U.S. Preventive Services Task Force (USPSTF) posted a final recommendation statement and evidence summaries on...
Functional MRI Assesses Crocodile Brain Listening to Classical Music

A research team from Ruhr-Universität Bochum (RUB) used functional MRI to assess the brain patterns of a Nile crocodile and determine what happens when the animal hears complex sounds. Image courtesy of Felix Ströckens, M.D./Proceedings of the Royal Society B: Biological Sciences

News | Magnetic Resonance Imaging (MRI) | May 08, 2018
May 8, 2018 — In a first, an international research team from the Department of Biopsychology at Ruhr-Universität Boc
7T MRI Provides Precise 3-D Maps of Brain Activity

fMRI of a patient with secondary glioblastoma (brain tumor). Functional localization was measured before surgery by means of a motor task (hand opening and closing). On the left, the uncorrected scan, on the right the result after dynamic image correction. Image courtesy of Quelle: MUW/ High Field MR Centre of Excellence

 

News | Magnetic Resonance Imaging (MRI) | May 03, 2018
With the support of the Austrian Science Fund FWF, researchers from Vienna have developed methods to improve functional...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
Esaote Change of Ownership Completed
News | Ultrasound Imaging | April 30, 2018
The acquisition of biomedical equipment company Esaote SpA’s share capital was completed on April 19, the company...
Overlay Init